The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Open accessAbstract
BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65). CONCLUSIONS: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers. PATIENT SUMMARY: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., Gohagan, J., Berg, C. D., & Prorok, P. C. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.334 · Cited by 191
Self-citation
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Epidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
Wei, J. T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., Fine, S. W., Han, M., Kim, S. K., Kirkby, E., et al. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003491 · Cited by 391
Self-citation
Metadata
- Authors
- Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., Evans, D. G., Rothwell, J., Maehle, L., Grindedal, E. M., James, P., Mascarenhas, L., McKinley, J., Side, L., Thomas, T., van Asperen, C., Vasen, H., Kiemeney, L. A., Ringelberg, J., Jensen, T. D., Osther, P. J. S., Helfand, B. T., Genova, E., Oldenburg, R. A., Cybulski, C., Wokolorczyk, D., Ong, K.-R., Huber, C., Lam, J., Taylor, L., Salinas, M., Feliubadaló, L., Oosterwijk, J. C., van Zelst-Stams, W., Cook, J., Rosario, D. J., Domchek, S., Powers, J., Buys, S., O'Toole, K., Ausems, M. G. E. M., Schmutzler, R. K., Rhiem, K., Izatt, L., Tripathi, V., Teixeira, M. R., Cardoso, M., Foulkes, W. D., Aprikian, A., van Randeraad, H., Davidson, R., Longmuir, M., Ruijs, M. W. G., Helderman van den Enden, A. T. J. M., Adank, M., Williams, R., Andrews, L., Murphy, D. G., Halliday, D., Walker, L., Liljegren, A., Carlsson, S., Azzabi, A., Jobson, I., Morton, C., Shackleton, K., Snape, K., Hanson, H., Harris, M., Tischkowitz, M., Taylor, A., Kirk, J., Susman, R., Chen-Shtoyerman, R., Spigelman, A., Pachter, N., Ahmed, M., Ramon y Cajal, T., Zgajnar, J., Brewer, C., Gadea, N., Brady, A. F., van Os, T., Gallagher, D., Johannsson, O., Donaldson, A., Barwell, J., Nicolai, N., Friedman, E., Obeid, E., Greenhalgh, L., Murthy, V., Copakova, L., Saya, S., McGrath, J., Cooke, P., Rønlund, K., Richardson, K., Henderson, A., Teo, S. H., Arun, B., Kast, K., Dias, A., Aaronson, N. K., Ardern-Jones, A., Bangma, C. H., Castro, E., Dearnaley, D., Eccles, D. M., Tricker, K., Eyfjord, J., Falconer, A., Foster, C., Gronberg, H., Hamdy, F. C., Stefansdottir, V., Khoo, V., Lindeman, G. J., Lubinski, J., Axcrona, K., Mikropoulos, C., Mitra, A., Moynihan, C., Rennert, G., Suri, M., Wilson, P., Dudderidge, T., Offman, J., Kote-Jarai, Z., Vickers, A., Lilja, H., & Eeles, R. A.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 76
- Issue
- 6
- Pages
- 831-842
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2974215038
- Cited by
- 247
- References
- 1
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. https://app.cochat.ai/papers/10.1016/j.eururo.2019.08.019
- The paper
- Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., Evans, D. G., Rothwell, J., Maehle, L., Grindedal, E. M., James, P., Mascarenhas, L., McKinley, J., Side, L., Thomas, T., . . . Eeles, R. A. (2019). Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology. https://doi.org/10.1016/j.eururo.2019.08.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.